Who are the institutional investors buying aerovate Therapeutics stock?
AVTE stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc., Bank of America Corp DE, and Citigroup Inc.. Which institutional investors are buying Aerovate Therapeutics stock?
Is the Aerie Pharmaceuticals (Aeri) share price up 18% in a week?
It's nice to see the Aerie Pharmaceuticals, Inc. ( NASDAQ:AERI ) share price up 18% in a week. But only the myopic... Aerie (AERI) delivered earnings and revenue surprises of -16.13% and 0.63%, respectively, for the quarter ended September 2021.
Will Atara Biotherapeutics participate in a cell therapy panel at Cowen Conference?
SOUTH SAN FRANCISCO, Calif., March 02, 2022--Atara Biotherapeutics will participate in a cell therapy panel discussion at the Cowen 42nd Annual Healthcare Conference on March 9 at 9:10 a.m. EST. Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021.
See more
Aerami Therapeutics Valuation & Funding
Aerami Therapeutics Comparisons
This information is available in the PitchBook Platform. To explore Aerami Therapeutics‘s full profile, request access.
Aerami Therapeutics Signals
Developer of therapies intended for the treatment of severe respiratory and chronic diseases. The company offers inhaled
Aerami Therapeutics Investors
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Aerie Pharmaceuticals (AERI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
This information is available in the PitchBook Platform. To explore Aerami Therapeutics‘s full profile, request access.
Market Sentiment Around Loss-Making Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Teen Retailer Has Doubled in Size in 5 Years
With the business potentially at an important milestone, we thought we'd take a closer look at Aerie Pharmaceuticals...
Executive shakeup continues at Durham pharma in wake of CEO change
Retail has always been a tough business, so when you see a brand growing fast, you need to dig in and see what's going on -- fast.
Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635 (c) (4)
Two top executives at the public company headquartered in Durham will leave their roles at the end of February, months after the company's previous CEO left.
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
DURHAM, N.C., December 22, 2021--Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635 (c) (4)
About Aerovate Therapeutics
DURHAM, N.C., December 16, 2021--Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
3.5 Analyst's Opinion
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
Is Aerovate Therapeutics a buy right now?
Aerovate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
When is Aerovate Therapeutics' next earnings date?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last year. There are currently 5 buy ratings for the stock.
How were Aerovate Therapeutics' earnings last quarter?
Aerovate Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022. View our earnings forecast for Aerovate Therapeutics.
What price target have analysts set for AVTE?
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) issued its quarterly earnings results on Sunday, November, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.26). View Aerovate Therapeutics' earnings history.
Who are some of Aerovate Therapeutics' key competitors?
5 brokers have issued 12-month price targets for Aerovate Therapeutics' stock. Their forecasts range from $21.00 to $24.00. On average, they anticipate Aerovate Therapeutics' stock price to reach $22.33 in the next year.
Who is the CEO of Atara Biotherapeutics?
Some companies that are related to Aerovate Therapeutics include ADVANZ PHARMA (CXRXF), Organogenesis (ORGO), AnaptysBio (ANAB), Centessa Pharmaceuticals (CNTA), Tango Therapeutics (TNGX), Syndax Pharmaceuticals (SNDX), Aclaris Therapeutics (ACRS), Arcutis Biotherapeutics (ARQT), Celularity (CELU), Catalyst Pharmaceuticals (CPRX), Design Therapeutics (DSGN), Heron Therapeutics (HRTX), Collegium Pharmaceutical (COLL), Vanda Pharmaceuticals (VNDA) and uniQure (QURE). View all of AVTE's competitors..
What is ATRA T cell?
(Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will participate in a fireside chat at the Cowen Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 12:40 p.m. EDT.
What is ATRA 2021?
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ transplantation (SOT). The results are fea
What is Atara Bio?
SOUTH SAN FRANCISCO, Calif., July 02, 2021--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 124,580 restricted stock units of Atara’s common stock to 35 newly hired employees and stock options to purchase an aggregate of 99,585 shares of Atara’s common stock to 12 such newly hired emplo
When did Alkami go public?
Atara is a biopharmaceutical company with a focus on allogenic T-cell immunotherapy, a promising pathway to treatments for patients with serious diagnoses, including autoimmune diseases, hematologic cancers, and solid tumor cancers.
